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Surgical Infection Society Article
Are Patients with Perforated Peptic Ulcers Who
are Negative for Helicobacter pylori at a Greater Risk?
Rohit K. Rasane,1 Christopher B. Horn,2 Adrian A. Coleoglou Centeno,3 Nicholas B. Fiore,1
Marlon Torres Barboza,4 Qiao Zhang,1 Kelly M. Bochicchio,1 Laurie J. Punch,1
Grant V. Bochicchio,1 and Obeid N. Ilahi1
Abstract
Background: The link between Helicobacter pylori infection and peptic ulceration is well established. Recent
studies have reported a decrease of H. pylori-related peptic ulcer disease; Helicobacter pylori eradication is likely
the cause of this decrease. We hypothesized that patients with H. pylori-positive perforated peptic ulcer disease
(PPUD) requiring surgical intervention had worse outcomes than patients with H. pylori-negative PPUD.
Patients and Methods: A prospectively collected Acute and Critical Care Surgery registry spanning the years
2008 to 2015 was searched for patients with PPUD and tested for H. pylori serum immunoglobulin G (IgG) test.
Patients were divided into two cohorts: H. pylori positive (HPP) and H. pylori negative (HPN). Demographics,
laboratory values, medication history, social history, and esophagogastroduodenoscopy were collected. Student
t-test was used for continuous variables and w2 test was used for categorical variables. Linear regression was
applied as appropriate.
Results: We identified 107 patients diagnosed with PPUD, of whom 79 (74%) patients had H. pylori serum IgG
testing. Forty-two (53.2%) tested positive and 37 (46.8%) tested negative. Helicobacter pylori-negative PPUD
was more frequent in females (70.27%, p = 0.004), whites (83.78%, p = 0.001) and patients with higher body
mass index (BMI) 28.81 – 8.8 (p = 0.033). The HPN group had a lower serum albumin level (2.97 – 0.96 vs.
3.86 – 0.91 p = 0.0001), higher American Society of Anesthesiologists (ASA; 3.11 – 0.85 vs. 2.60 – 0.73;
p = 0.005), and Charlson comorbidity index (4.81 – 2.74 vs. 2.98 – 2.71; p = 0.004). On unadjusted analysis the
HPN cohort had a longer hospital length of stay (LOS; 20.20 – 13.82 vs. 8.48 – 7.24; p = 0.0001), intensive care
unit (ICU) LOS (10.97 – 11.60 vs. 1.95 – 4.59; p = 0.0001), increased ventilator days (4.54 – 6.74 vs. 0.98 – 2.85;
p = 0.004), and higher rates of 30-day re-admission (11; 29.73% vs. 5; 11.91%; p = 0.049). Regression models
showed that HPN PPUD patients had longer hospital and ICU LOS by 11 days (p = 0.002) and 8 days
(p = 0.002), respectively, compared with HPP PPUD.
Conclusion: In contrast to our hypothesis, HPN patients had clinically worse outcomes than HPP patients.
These findings may represent a difference in the baseline pathophysiology of the peptic ulcer disease process.
Further investigation is warranted.
Keywords: H. pylori; peptic ulcer; perforation
Helicobacter pylori infection has been consideredthe most important cause of peptic ulcer disease since
the 1980s [1]. Recent studies have reported a decrease in
H. pylori-positive (HPP) peptic ulcer disease [2–4]. This re-
ported decreased incidence of H. pylori infection is partly the
result of optimizing sanitation, public health education ef-
forts, and a lower childhood acquisition rate [5]. Graham [6]
concluded that if the absolute number of H. pylori-negative
(HPN) idiopathic ulcers remained constant and the incidence of
HPP ulcers decreased, a greater proportion of HPN idiopathic
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ulcers would be diagnosed. Contrary to Graham’s hypothesis,
Hung et al. [7] reported that from 1997 to 2000 the true incidence
of HPN bleeding ulcers had increased four-fold [7].
Recurrent ulcer disease after peptic ulcer perforation oc-
curs mainly in patients with H. pylori infection, which sug-
gests that micro-organisms play an important role in
complications [8]. We hypothesized that in patients with
perforated peptic ulcer disease (PPUD) requiring surgical
intervention, positive H. pylori serology has worse outcomes
than negative serology.
Patients and Methods
A prospectively collected and maintained Acute and Cri-
tical Care Surgery (ACCS) registry spanning 2008 to 2015
was searched for patients diagnosed with perforated peptic
ulcer (ICD-9 codes 531.1x, 531.2x, 531.5x, 531.6x, 532.1x,
532.2x, 532.5x, 532.6x, and 533.9) requiring emergent op-
erative management. A total of 107 patients were seen in the
emergency department who were diagnosed with PPUD and
required surgical intervention. The diagnosis and anatomic
location of PPUD was based on the operative findings. Pa-
tients were excluded if the etiology of the perforation was
caused by ischemia or vascular pathology.
Post-operative serum anti-H. pylori immunoglobulin G
(IgG) testing was abstracted and patients without serology
were excluded from the study. On the basis of the results of
the anti-H. pylori IgG test, the patients were divided into HPP
and HPN cohorts.
Demographics such as age, gender, race, and body mass
index (BMI) were abstracted. Laboratory values such as he-
moglobin and albumin levels were similarly abstracted. Past
medical history including non-steroidal anti-inflammatory
drug (NSAID) use, history of gastroesophageal reflux disease
(GERD), proton pump inhibitor (PPI) use, dyslipidemia, and
peptic ulcer disease history was evaluated and compared.
Social history (smoking, drug, and alcohol use) was also
collected. We evaluated the outcomes, hospital length of
stay (LOS), intensive care unit (ICU) LOS, ventilator days,
30-day re-admission and mortality. Post-operative upper
Table 1. Demographics and Patient Characteristics
Total HPP HPN p
n 79 42 (53.16%) 37 (46.84%)
Age 56.89 (– 16.51) 50.45 (– 16.06) 64.19 (– 13.92) 0.0001
Gender 0.004
Male 37 (46.84%) 26 (61.90%) 11 (29.73%)
Female 42 (53.16%) 16 (38.10%) 26 (70.27%)
Race 0.001
Asian 2 ( 2.53%) 2 ( 4.76%) 0 ( 0%)
African American 27 (34.19%) 21 (50.00%) 6 (16.22%)
White 47 (59.49%) 16 (38.10%) 31 (83.78%)
Other 3 ( 3.79%) 3 ( 7.14%) 0 ( 0%)
BMI 26.9 (– 7.43) 25.13 (– 5.35) 28.81 (– 8.81) 0.033
Smoking 39 (49.37%) 27 (69.23%) 12 (30.77%) 0.008
Alcohol use 23 (29.11%) 13 (56.52%) 10 (43.48%) 0.940
Drugs 9 (11.39%) 7 (77.78%) 2 (22.22%) 0.277
NSAID use 39 (49.37%) 16 (38.10%) 23 (62.16%) 0.033
GERD 13 (16.50%) 9 (69.23%) 4 (30.77%) 0.204
Location 0.430
Stomach 25 (31.65%) 14 (33.33%) 11 (29.73%)
Duodenum 40 (50.63%) 19 (45.24%) 21 (56.76%)
Pyloric channel 11 (13.92%) 8 (19.05%) 3 ( 8.10%)
Stomach and duodenum 3 ( 3.80%) 1 ( 2.38%) 2 ( 5.41%)
Hemoglobin 13.10 (– 2.90) 13.75 (– 2.45) 12.36 (– 3.20) 0.032
Lymphocyte % 8.51 (– 6.43) 9.63 (– 6.74) 7.24 (– 5.90) 0.100
Monocyte % 4.98 (– 3.72) 4.92 (– 4.30) 5.04 (– 3.00) 0.889
Platelets 301.50 (–176.60) 297.52 (–198.14) 305.946 (–151.10) 0.834
Albumin 3.45 (– 1.03) 3.86 (– 0.91) 2.97 (– 0.96) 0.0001
PT 14.54 (– 11.10) 12.98 (– 4.38) 16.14 (– 15.11) 0.219
INR 1.27 (– 0.99) 1.12 (– 0.38) 1.43 ( 1.34) 0.180
ASA 2.83 (– 0.83) 2.60 (– 0.73) 3.11 (– 0.85) 0.005
Charlson comorbidity index 3.84 (– 2.86) 2.98 (– 2.71) 4.81 (– 2.74) 0.004
Time from perforation to repair 0.27 (– 0.55) 0.29 (– 0.51) 0.24 (– 0.60) 0.733
LOS 13.96 (– 12.25) 8.48 (– 7.24) 20.20 (– 13.82) <0.0001
ICU LOS 6.18 (– 9.68) 1.95 (– 4.59) 10.97 (– 11.60) <0.0001
Ventilator days 2.65 (– 5.33) 0.98 (– 2.85) 4.54 (– 6.74) 0.004
UGI barium leak (n = 47) 6 (12.77%) 1 ( 2.13%) 5 (10.64%) 0.029
Mortality 3 ( 3.80%) 1 ( 2.40%) 2 ( 5.41%) 0.483
Statistically significant differences are in bold.
HPN = Helicobacter pylori-negative; HPP = Helicobacter pylori-positive; BMI = body mass index; NSAID = non-steroidal anti-
inflammatory drug; GERD = gastroesophageal reflux disease; PT = prothrombin time; INR = international normalized ratio; ASA = Amer-
ican Society of Anesthesiologists; ICU = intensive care unit; LOS = length of stay; UGI = upper gastrointestinal.















































gastrointestinal Gastrografin (Liebel-Flarsheim, North Car-
olina) study and esophagogastroduodenoscopy (EGD) data
were collected if done.
The w2 test was used for testing associations between cate-
gorical variables and Student t-test was used for continuous
variables. Risk factors and outcomes between the two groups
(HPP and HPN perforated peptic ulcer), seen on univariable
analysis were subjected to multivariable analysis as appropriate.
In all analyses, a two-sided p value of <0.05 was regarded as
significant. Statistical Package for Social Sciences (SPSS, ver-
sion 23.0; IBM Corp., Armonk, NY) was used for data analysis.
Results
Of the 107 patients diagnosed with PPUD requiring emer-
gent operative management, 79 (74%) patients had anti-
H. pylori IgG serology performed. The serology testing was
done on average two days (–2 days).
Of the 79 patients included in the study, 42 (53.16%) were
female and 37 (46.84%) were male. The mean age of our
patients was 56.89 – 16.51 years. Perforated peptic ulcer
disease was most common in whites (59.49%) followed by
African American (34.19%), Asian (2.53%), and others
(3.79%; Table 1). The most common site of the perforated
peptic ulcer was: duodenum, 40 (50.60%); stomach, 25
(31.70%); pyloric channel, 11 (13.90%); and both stomach
and duodenum simultaneously, 3 (3.80%; Table 1).
The result of the serum anti-H. pylori IgG test showed that
42 (53.16%) were HPP and 37 (46.84%) were HPN. Patients
with HPN PPUD had higher BMI than the HPP group
(28.81 – 8.81 vs. 25.13 – 5.35, p = 0.033). Patients with HPP
PPUD were more likely to be smokers than those in the HPN
cohort (27, 69.23% vs. 12, 30.77%; p = 0.008), however, there
was no difference found between the cohorts with respect to
alcohol or drug history (Table 1). Patients with HPN PPUD
were more likely to be on an NSAID pre-operatively (23,
62.16% vs. 16, 38.10%; p = 0.033), with duodenum (50.60%)
being the most common location to be related with the per-
forated peptic ulcers after the use of NSAID (Table 2). No
difference was seen between the cohorts in relation to proton
pump inhibitor (PPI) use. Pre-operative laboratory reports
showed that the HPN group had lower hemoglobin levels
(12.36 – 3.20 vs. 13.75 – 2.45; p = 0.032), and serum albumin
levels (2.97 – 0.96 vs. 3.86 – 0.91; p = 0.0001; Table 1). The
ASA and Charlson comorbidity index in the HPN group was
3.11 – 0.85 and 4.81 – 2.74, respectively, which was higher
than the HPP group 2.6 – 0.73 and 2.98 – 2.71, respectively
(p = 0.005 and p = 0.004, respectively; Table 1). The time from
the diagnosis of the perforation to repair was similar in be-
tween cohorts (0.29 – 2.71 vs. 0.24 – 0.60, p = 0.733; Table 1).
In univariable analysis, the patients with HPN had a sub-
stantially longer hospital LOS (20.20 – 13.82 vs. 8.48 – 7.24,
p < 0.0001), longer ICU LOS (10.97 – 11.60 vs. 1.95 – 4.59,
p < 0.0001), and more ventilator days (4.54 – 6.74 vs. 0.98 –
2.85, p = 0.004). They also had a higher re-admission rate
of 30 days compared with the HPP group (11, 29.73% vs. 5,
11.91%, p = 0.049), there was, however, no difference in
mortality (Table 1).
Post-operatively, patients underwent upper gastrointesti-
nal Gastrografin (UGI) study to search for a leak. Forty-seven
(59.50%) patients had an UGI, of whom 41 (87.23%) did not
have a leak. Of the remaining six patients, five (10.64%) from
the HPN group and only one (2.13%) patient from the HPP
group had a leak (p = 0.029; Table 1).
Of the patients followed post-operatively for continued
symptomatic suspicion for recurrence, patients underwent an
EGD on post-operative day 78 (–45.48). Of the nine patients
who underwent an EGD, one (11.1%) patient had a normal
EGD and eight (88.9%) patients were found to have a re-
current ulcer. Three (37.5%) of the patients with recurrent
ulcers had an associated bleed.
Table 2. Non-Steroidal Anti-Inflammatory




Stomach 13 (32.5%) 12 (30.77%) 25 (31.7%)
Duodenum 17 (42.5%) 23 (58.97%) 40 (50.6%)
Pyloric channel 8 (20.0%) 3 ( 7.70%) 11 (13.9%)
Stomach and
duodenum
2 ( 5.0%) 1 ( 2.56%) 3 ( 3.8%)
Total 40 39 79
NSAID = non-steroidal anti-inflammatory drug.
Table 3. Linear Regression of Length of Stay
Parameters Coefficient 95% CI p
HPN 10.87 4.26–17.47 0.002
Age -0.15 -0.40– 0.11 0.251
BMI 0.39 -0.16– 0.94 0.157
Gender -1.18 -7.62– 5.25 0.714
Smoking -0.75 -7.44– 5.93 0.822
NSAID use -3.99 -11.33– 3.35 0.280
Albumin -1.46 -5.74– 2.82 0.496
Hemoglobin 0.14 -1.16– 1.44 0.832
ASA 2.82 -1.71– 7.35 0.217
Charlson comorbidity
index
1.11 -0.79– 3.02 0.249
Statistically significant differences are in bold.
CI = confidence interval; HPN = Helicobacter pylori-negative;
BMI = body mass index; NSAID = non-steroidal anti-inflammatory
drug; ASA = American Society of Anesthesiologists.
Table 4. Linear Regression of Intensive
Care Unit Length of Stay
Parameters Coefficient 95% CI p
HPN 8.11 3.13–13.10 0.002
Age -0.09 -0.28– 0.11 0.368
BMI 0.36 -0.06– 0.77 0.088
Gender 0.51 -4.34– 5.36 0.834
Smoking 1.90 -3.14– 6.94 0.453
NSAID use -2.57 -8.10– 2.07 0.357
Albumin -0.59 -3.82– 2.64 0.716
Hemoglobin -0.27 -1.25– 0.71 0.585
ASA 3.33 -0.09– 6.75 0.056
Charlson comorbidity
index
0.71 -0.73– 2.15 0.328
Statistically significant differences are in bold.
CI = confidence interval; HPN = Helicobacter pylori-negative;
BMI = body mass index; NSAID = non-steroidal anti-inflammatory
drug; ASA = American Society of Anesthesiologists.















































We performed multiple linear regression models to adjust
for potential outcome confounders. In a linear regression
model with LOS as the outcome, HPN PPUD was found to be
an independent risk factor for longer LOS (10.87; confidence
interval [CI] 4.26–17.47, p = 0.002; Table 3), similarly with
ICU LOS as the outcome, HPN PPUD was again found to be
an independent risk factor for longer ICU LOS (8.11; CI
3.13–13.10, p = 0.002; Table 4). However, with ventilator
days as the outcome, H. pylori negativity did not have an
impact (Table 5).
Discussion
According to previous studies, anti-H. pylori serology
testing can be used to differentiate the HPP and HPN popu-
lation. The sensitivity and specificity of all commercially
available test kits range from 76%–84% and 79%–90%, re-
spectively [9,10]. The serology test is simple, inexpensive,
rapid, accurate, and is useful to assess the global presence of H.
pylori even when the bacteria are irregularly distributed on the
gastric mucosa [11,12]. Studies also show similarities between
the various tests for the detection of H. pylori [13]. In our study,
home medications did not reveal antibiotic use that would
eradicate H. pylori, causing negative H. pylori results. How-
ever, the early phase of H. pylori infection before IgG sero-
conversion takes place should be considered in acute PPUD.
In our population the prevalence of H. pylori infection in
patients with acute PPUD was 53%, which is similar to the
study done by Reinbach et al. [14] who found a prevalence of
50%. Only 11.4% of our patients were found to have a previous
history of peptic ulcer disease, which is lower than the study by
Reinbach et al. [14], however, they reported only perforated
duodenal ulcers. As a result of operative evaluation, our pap-
tient population had acute PPUD that was not chronic disease.
Helicobacter pylori-negative disease is increasing [15–
19]. The role of acid in the pathogenesis of HPN ulcers re-
mains controversial. el-Omar et al. [20] summarized that
disturbance in regulation of acid secretion are likely relevant
to the mechanism by which H. pylori infection predisposes to
duodenal ulceration, however, a Japanese study found only
one-third of patients with idiopathic ulcers had acid hyperse-
cretion [21]. In our study, only 41% of the patients used PPIs
prior to development of the perforation, however, there was no
difference in the use of a PPI and development of HPP or HPN
perforated peptic ulcer, which supports the study done by
Verdu et al. [22]. Several studies have been conducted to
elucidate the role of NSAID use in the development of HPN
ulcer disease [4,14,18,23–27]. Fifty percent of our patients had
a history of NSAID use. Helicobacter pylori-negative perfo-
rated ulcers were substantially higher (60%) in the patients
with NSAID use, which was consistent with previous studies
[14,18,23–25]. Our data suggests that ulcers caused by NSAID
use may not be related to the H. pylori infection.
Our study shows that the HPN group had lower hemo-
globin levels than the HPP group, which is in contrast to
previous studies that showed that anemia and HPP ulcers are
related [28–30] and that treatment of H. pylori infection could
be effective in improving anemia [31]. Our patient population
is also unique because the HPN group had lower albumin
levels suggesting malnutrition and immunosuppression, which
contrasts studies in which it was found that the serum albumin
levels improved after H. pylori eradication [32,33]. The higher
rate of re-bleeding or recurrent ulcer formation in the HPN
group in our cohort echoed the findings in the previous
studies [7,34,35].
This study also shows that the HPN group of patients had
almost 10 times longer ICU stay and four times longer ven-
tilator days along with more than twice longer length of stays
than the HPP group. The HPN group had higher ASA grade
and higher Charlson comorbidity index. The finding of higher
ASA grades and Charlson comorbidity indices along with the
lower albumin levels in patients with HPN disease suggest
that the baseline pathophysiology of HPN PPUD is different
than the HPP perforations.
Although our study indicates substantial trends, we were
limited by the unavailability of ulcer histology, tissue cultures
for H. pylori, and other non-invasive testing for H. pylori not
feasible in an in-patient setting. Furthermore, loss to follow-up
may also be a factor. Another notable limitation of the study
was the number of patients and the single-center design.
In summary, HPN patients are older and sicker on presen-
tation. Helicobacter pylori-negative status is an independent
risk factor for increased hospital and ICU LOS, conferring an
11-day and eight-day increase, respectively. Ninety percent of
patients with HPN and a clinical suspicion of recurrent disease
had a positive EGD for ulcer or ulcer with bleed suggesting
awareness for earlier evaluation during follow-up. Lower he-
moglobin and albumin levels and LOS along with higher ASA
score and Charlson comorbidity index suggest that the HPN
perforated peptic ulcers may have a different pathophysiology.
Further research is needed to understand etiology of worse
outcomes in HPN PPUD patients.
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